These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 18576907

  • 21. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 22. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
    Jennings DL, Taber DJ.
    Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
    [Abstract] [Full Text] [Related]

  • 23. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S.
    Kyobu Geka; 2007 Jun; 60(6):484-7. PubMed ID: 17564066
    [Abstract] [Full Text] [Related]

  • 24. Pharmacologic therapies across the continuum of left ventricular dysfunction.
    Abraham WT, Greenberg BH, Yancy CW.
    Am J Cardiol; 2008 Sep 08; 102(5A):21G-28G. PubMed ID: 18722188
    [Abstract] [Full Text] [Related]

  • 25. Reassessing guidelines for heart failure.
    Drexler H, Wollert KC.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 08; 5 Suppl 1():S28-33. PubMed ID: 15526240
    [Abstract] [Full Text] [Related]

  • 26. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K.
    Am J Cardiovasc Drugs; 2002 Sep 08; 2(1):1-6. PubMed ID: 14727993
    [Abstract] [Full Text] [Related]

  • 27. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient.
    Scott RL.
    Cardiol Clin; 2008 Feb 08; 26(1):73-7, vii. PubMed ID: 18312907
    [Abstract] [Full Text] [Related]

  • 28. Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
    Thadani U, Jacob RG.
    Drugs Today (Barc); 2008 Dec 08; 44(12):925-37. PubMed ID: 19198701
    [Abstract] [Full Text] [Related]

  • 29. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan 08; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 30. Treatment of heart failure with abnormal left ventricular systolic function in the elderly.
    Aronow WS.
    Clin Geriatr Med; 2007 Feb 08; 23(1):61-81. PubMed ID: 17126755
    [Abstract] [Full Text] [Related]

  • 31. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM.
    Arch Intern Med; 2007 Oct 08; 167(18):1930-6. PubMed ID: 17923591
    [Abstract] [Full Text] [Related]

  • 32. Chronic heart failure: an overview of conventional treatment versus novel approaches.
    Landmesser U, Drexler H.
    Nat Clin Pract Cardiovasc Med; 2005 Dec 08; 2(12):628-38. PubMed ID: 16306919
    [Abstract] [Full Text] [Related]

  • 33. [Hypotension associated with heart failure].
    Fujita H.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():375-82. PubMed ID: 17571409
    [No Abstract] [Full Text] [Related]

  • 34. Heart failure in women: a need for prospective data.
    Hsich EM, Piña IL.
    J Am Coll Cardiol; 2009 Aug 04; 54(6):491-8. PubMed ID: 19643307
    [Abstract] [Full Text] [Related]

  • 35. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN, A-HeFT Investigators.
    Am J Cardiovasc Drugs; 2007 Aug 04; 7(5):373-80. PubMed ID: 18041162
    [Abstract] [Full Text] [Related]

  • 36. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG.
    Eur Heart J; 2005 Dec 04; 26(24):2706-13. PubMed ID: 16183692
    [Abstract] [Full Text] [Related]

  • 37. Neurohormones and heart failure: the importance of aldosterone.
    Odedra K, Ferro A.
    Int J Clin Pract; 2006 Jul 04; 60(7):835-46. PubMed ID: 16846401
    [Abstract] [Full Text] [Related]

  • 38. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
    Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, Unger T, Volpe M, Waeber B, Zannad F.
    Blood Press; 2005 Jul 04; 14(4):196-209. PubMed ID: 16126553
    [Abstract] [Full Text] [Related]

  • 39. [Effect of combination therapy with angiotensin II type I receptor and aldosterone receptor blockers in heart failure].
    Aoyama N.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():145-9. PubMed ID: 17569312
    [No Abstract] [Full Text] [Related]

  • 40. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U, Wollert KC, Drexler H.
    Cardiovasc Res; 2009 Feb 15; 81(3):519-27. PubMed ID: 19019834
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.